CytoDyn Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jacob Lalezari
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1111 Main Street Vancouver WA United States of America 98660
- IPO Date
- Dec 13, 2006
- CIK
- 0001175680
- Website
- cytodyn.com
- Similar Companies
- Business
- CytoDyn Inc. (CYDY) is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor for multiple therapeutic indications including solid-tumor oncology, infectious diseases, and inflammatory conditions; its pipeline encompasses Phase 2 trials for triple-negative breast cancer, metastatic colorectal cancer, metabolic dysfunction-associated steatohepatitis (MASH), chronic inflammation, acute and long COVID-19, and HIV antiviral therapy, with Phase 3 ongoing for HIV and preclinical efforts in glioblastoma, prostate cancer, Alzheimer's disease, HIV post-exposure prophylaxis, and stem cell transplantation for HIV cure. Founded in 2002 and headquartered in Vancouver, Washington, the company operates primarily in the United States with a strategic emphasis on oncology and immunology targeting patient populations suffering from cancers such as metastatic triple-negative breast cancer, inflammatory disorders, and HIV. In November 2025, CytoDyn secured a $30 million equity funding commitment from Yorkville Advisors Global to advance leronlimab programs, particularly research on PD-L1 upregulation, providing flexible capital over 36 months without minimum commitments or operational restrictions; recent milestones include FDA clearance for its Phase II oncology trial in late 2024 conducted with Syneos Health.
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease
CytoDyn to Present at the LD Micro Invitational XVI
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
CytoDyn to Host Investor Webcast
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
CytoDyn to Present at the AACR Annual Meeting 2026
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
Head-To-Head Review: BeOne Medicines (NASDAQ:ONC) versus CytoDyn (OTCMKTS:CYDY)
Ironwood Pharmaceuticals (NASDAQ:IRWD) & CytoDyn (OTCMKTS:CYDY) Critical Survey
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
December 2025 Letter to Shareholders
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
CytoDyn Announces Resolution of Class Action Lawsuit
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
CytoDyn Secures $30 Million Commitment from Yorkville Advisors